Results 51 to 60 of about 917,566 (209)
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
Systemic mastocytosis – a diagnostic challenge
Mastocytosis refers to a group of disorders characterized by the infiltration of clonally derived mast cells to the skin or extracutaneous tissues resulting in a heterogeneous clinical picture. It is a rare hematologic disorder in all its forms. The exact incidence is unknown; it affects patients of any age and males and females equally.
Lladó, AC +3 more
openaire +4 more sources
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley +1 more source
Post‐Hoc Long‐Read Sequencing Links Leukemic Mutation Status to Single‐Cell Transcriptomes
ABSTRACT Single‐cell RNA‐sequencing‐based characterization of cells that belong to the neoplastic clone is a major challenge in hematologic neoplasms, where malignant and normal cells coexist. Confident molecular profiling requires simultaneous analysis of gene expression and genetic mutations in individual cells, an ability that is not supported by ...
Sofia Papavasileiou +8 more
wiley +1 more source
ICSH Guidance on Bone Marrow Examination and Reporting
ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber +6 more
wiley +1 more source
ABSTRACT Gilvetmab is a caninised monoclonal antibody against canine PD‐1. Concurrent or sequential administration of anti‐PD‐1 antibodies and radiation therapy (RT) improves survival time in various species. Eighteen dogs with mast cell tumours (MCTs) were prospectively treated with 24 Gy of RT over Days 0, 7 and 21 and gilvetmab every 2 weeks ...
Tiffany W. Martin +2 more
wiley +1 more source
A 64-year-old man was admitted to the hematology ward due to neutropenia and thrombocytopenia. The only symptom in the month preceding his admission, was significant weight loss.
Rontogianni, Dimitra +5 more
openaire +2 more sources
Exosomal miR‐146a‐5p is identified as a pivotal regulator in steroid‐induced osteonecrosis. Its reduction activates NF‐κB signaling, compromises mitophagy, and disrupts mitochondrial bioenergetics, resulting in autophagic disequilibrium. Engineered exosomes delivering miR‐146a‐5p reinstate mitochondrial function, augment oxidative phosphorylation and ...
Zehui Lv +13 more
wiley +1 more source
SYSTEMIC MASTOCYTOSIS ASSOCIATED WITH MINIMAL CHANGE DISEASE [PDF]
Systemic Mastocytosis (SM) has not previously been reported in association with minimal change disease (MCD). Mastocytosis is a rare myeloproliferative disease that is characterised by uncontrolled proliferation of aberrant mast cells. This can lead to a
Sophia Otto +3 more
core +5 more sources
Case Report: Treatment of systemic mastocytosis with sunitinib [version 1; referees: 2 approved]
Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme. Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to ...
Gerhard J. Molderings +3 more
doaj +1 more source

